Pharmaconenomic testing in psychiatry

Pharmacogenomics (PGx) in Psychiatry – Benefits of Personalized Prescribing

One of the concerns in mental health treatment is patient compliance. Our comprehensive program ACLSmh is designed and tailored to accommodate the needs of drug monitoring and testing for Mental Health Practitioners.


As a psychiatrist you may frequently find yourself challenged by patients with multiple health issues already taking several medications by the time they see you. Until recently, psychiatrists had little choice but to prescribe medications without knowing in advance how their patients might genetically respond. But no more: with personalized prescribing by ACLSmh™, you’ll know upfront what medications will likely prove to be most effective for your patient – and which ones will not. And you’ll know precisely how any medications will interact with the prescribed medications.

What is included in this test bundle?


The ACLSmh™ Urine Drug Test is specifically designed for mental health professionals as an effective way to monitor medications.


Obtaining drug test samples may be difficult in the mental health practice. Depending on the setting, it may not be possible or may be unreliable. This is why we designed the ACLSmh™ OFT, a reliable, verifiable Oral Fluid Test, available to be taken in almost any setting, with quantifiable and accurate results1.


90% of genetic variability has been contributed to a single nucleotide variation. A recent study suggests that the genetic variation of PIP4K2A is contributory to the poor response of some schizophrenic patients to antipsychotic therapy2. The ACLSmh™ PGx is pharmacogenetic testing geared specifically towards the mental health professional. With up to date knowledge and research driven practices, our team is able to provide expert genetic analysis to help avert drug failure and other potential issues.

ACLSmh™ testing is designed to:

  • Evaluate patient genetic variability that could potentially deem a particular drug ineffective.
  • Determine appropriate therapy for each patient, based on genetic variability.
  • Evaluate potential drug-drug interactions and susceptibility of each patient.
  • Improve informed consent by communicating current and future therapy trends specifically engineered for each individual.
  • ACLSmh™ testing is the foundation of personalized medicine and it will help us select the right drug at the right dose, for the right patient.

Psychiatric Medications with Pharmacogenetic Information on the FDA Label

AtomoxetineCYP2D6Fluoxetine and OlanzapineCYP2D6PimozideCYP2D6
Chlordiazepoxide and AmitriptylineCYP2D6FluvoxamineCYP2D6ProtriptylineCYP2D6
DoxepinCYP2C19 and CYP2D6ParoxetineCYP2D6

ACLSmh™ Helps You Achieve Optimal Prescribing

Virtually all of the medications used to treat psychiatric conditions are metabolized by CYP2D6, CYP2C19 or CYP3A4. ACLSmh™ includes testing of all clinically significant genetic variants: CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5, HTR2A, CYP1A2, COMT and ANKK1/DRD2.

ACLSmh™ Helps You with Polypharmacy Safety – Now and in the Future

Many psychiatric patients may also be battling heart disease, pain, cancer, or other conditions that make multiple prescriptions necessary. But a body’s limited capacity to process medications is easily slowed by competition between other drugs, herbals, and over-the-counters. This is further compromised in patients with genetic variations. Whether a patient is genetically a poor metabolizer or has become a poor metabolizer because of other medications, it’s been shown by prospective trials, population analyses, and case studies they can experience an increase in adverse drug events because of reduced elimination.

Which Patients Benefit Most from ACLSmh™?

The ACLSmh™ is pharmacogenomic testing geared specifically towards the mental health professional. With up to date knowledge and research driven practices, our team is able to provide expert genetic analysis to help avert drug failure and other potential issues.


  1. Encyclopedia of Mental Disorders
  2. Concheiro M, Gray T, Shakleya D, Huestis M. High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry. Analytical & Bioanalytical Chemistry [serial online]. September 15, 2010;398(2):915-924.
  3. Kaur H, Jajodia A, Kukreti R, et al. Genetic Variations of PIP4K2A Confer Vulnerability to Poor Antipsychotic Response in Severely Ill Schizophrenia Patients. Plos ONE [serial online]. July 2014;9(7):1-14